Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.45 |
| ▸ | PHGDH | O43175 | 1/20 | 0.42 |
| ▸ | MGLL | Q99685 | 1/20 | 0.42 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.40 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.40 |
| ▸ | RAD52 | P43351 | 1/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
| ▸ | OGFRL1 | Q5TC84 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL451992 | 1.00 | HTR6 (0.64) | HTR6KMT2AHPGDSMN1; SMN2HRH3 | |
| SCHEMBL943337 | 1.00 | HTR6 (0.64) | HTR6KMT2AHPGDSMN1; SMN2HRH3 | |
| SCHEMBL1267270 | 1.00 | HTR6 (0.64) | HTR6KMT2AHPGDSMN1; SMN2HRH3 | |
| SCHEMBL8695162 | 0.97 | HTR6 (0.61) | HTR6KMT2AHPGDSMN1; SMN2HRH3 | |
| Piperazine SCHEMBL27903046 | 0.97 | HTR6 (0.61) | HTR6KMT2AHPGDSMN1; SMN2HRH3 | |
| SCHEMBL28809524 | 0.97 | HTR6 (0.61) | HTR6KMT2AHPGDSMN1; SMN2HRH3 | |
| Hydrochloric Acid SCHEMBL572044 | 0.97 | HTR6 (0.61) | HTR6KMT2AHPGDSMN1; SMN2HRH3 | |
| Water SCHEMBL14860181 | 0.97 | HTR6 (0.61) | HTR6KMT2AHPGDSMN1; SMN2HRH3 | |
| Hydrochloric Acid SCHEMBL6499302 | 0.97 | HTR6 (0.61) | HTR6KMT2AHPGDSMN1; SMN2HRH3 | |
| SCHEMBL271868 | 0.97 | HTR6 (0.67) | HTR6KMT2AHPGDSMN1; SMN2HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1838 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119823621-A | Water-based intumescent fire-retardant coating as well as preparation method and application thereof | 亚士创能新材料(滁州)有限公司 | 2025-04-15 | — | — | CN | claimed |
| CN-119715885-A | Analysis method for detecting residual quantity of chloroethane and 2-chloropropane in 1-cyclohexylpiperazine | 江苏万邦生化医药集团有限责任公司 | 2025-03-28 | — | — | CN | claimed |
| CN-119569720-A | Synthesis method of 4- (4-chlorothienyl-2-yl) -5- (4-cyclohexylpiperazin-1-yl) thiazole-2-amine | 深圳智微通科技有限公司 | 2025-03-07 | — | — | CN | claimed |
| US-20250075147-A1 | FRAGRANCE AND FLAVOR COMPOSITIONS COMPRISING NEW FLAVOR AND FRAGRANCE INGREDIENTS | OSMO LABS, PBC | 2025-03-06 | — | — | US | claimed |
| CN-118684644-A | Eupatilin derivative containing piperazine structure and preparation method and application thereof | 南阳医学高等专科学校 | 2024-09-24 | — | — | CN | claimed |
| CN-118221721-A | Two-dimensional organic-inorganic lead perovskite material and preparation method thereof | 济宁学院 | 2024-06-21 | — | — | CN | claimed |
| US-20240115553-A1 | COMPOSITIONS AND METHODS FOR TREATING BRAIN INJURY | AZEVAN PHARMACEUTICALS, INC. (US) | 2024-04-11 | — | — | US | claimed |
| US-11787785-B2 | Pyrazolopyridine derivatives and uses thereof | NOVARTIS AG (CH) | 2023-10-17 | — | — | US | claimed |
| CN-115028604-B | Preparation method of cyclohexyl piperazine | 万华化学集团股份有限公司 | 2023-09-19 | — | — | CN | claimed |
| CN-116396271-A | Series of maleic acid atorvastatin impurities as well as preparation method and application thereof | 湖南先施制药有限公司 | 2023-07-07 | — | — | CN | claimed |
| EP-0994712-A1 | INHIBITORS OF NEUTROPHIL MEDIATED OXIDANT PRODUCTION | ELI LILLY AND COMPANY (US) | 2000-04-26 | — | — | EP | claimed |
| WO-1999002163-A1 | INHIBITORS OF NEUTROPHIL MEDIATED OXIDANT PRODUCTION | ELI LILLY AND COMPANY (US) | 1999-01-21 | — | — | WO | claimed |
| EP-0761219-A1 | 2-Acylaminopropanamines as growth hormone secretagogues | ELI LILLY AND COMPANY (US) | 1997-03-12 | — | — | EP | claimed |
| WO-1997007117-A1 | 2-ACYLAMINOPROPANAMINES AS GROWTH HORMONE SECRETAGOGUES | ELI LILLY AND COMPANY (US) | 1997-02-27 | — | — | WO | claimed |
| EP-0729468-A1 | NON-PEPTIDE TACHYKININ RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 1996-09-04 | — | — | EP | claimed |
| EP-0729468-A4 | NON-PEPTIDE TACHYKININ RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 1996-07-12 | — | — | EP | claimed |
| EP-0699674-A1 | 1-Aryl-2-acetylamidopentanone derivatives for use as tachykinin receptor antagonists | ELI LILLY AND COMPANY (US) | 1996-03-06 | — | — | EP | claimed |
| EP-0699665-A1 | Imidazoline derivatives, their preparation and their use as tachykinin receptor antagonists | ELI LILLY AND COMPANY (US) | 1996-03-06 | — | — | EP | claimed |
| EP-0686629-A2 | Cyclohexyl tachykinine receptor antagonists | ELI LILLY AND COMPANY (US) | 1995-12-13 | — | — | EP | claimed |
| WO-1995014017-A1 | NON-PEPTIDE TACHYKININ RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 1995-05-26 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11787785-B2 | Pyrazolopyridine derivatives and uses thereof | HBZ, ZFX, WIZ | HTR6 3197/4885KMT2A 1734/4885HPGD 1030/4885 |
| US-20240115553-A1 | COMPOSITIONS AND METHODS FOR TREATING BRAIN INJURY | FABP7, PYGB, CHAT | HTR6 2629/4885KMT2A 3500/4885HPGD 803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.